Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Need for Titration or Monitoring of Direct Oral Anticoagulant Treatment: The MONDOAC and KIDOAC study

Next Previous
Trial Profile

The Need for Titration or Monitoring of Direct Oral Anticoagulant Treatment: The MONDOAC and KIDOAC study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Therapeutic Use
  • Acronyms MONDOAC AND KIDOAC

    • Most Recent Events

    • 19 Oct 2021 Results (n=152)from KIDOAC assessing the inter-and intra-variability of drug concentrations in patients treated with DOACs in daily practice, published in the Journal of Thrombosis and Haemostasis
    • 14 Mar 2020 Results, assessing treatment satisfaction and patient concerns in patients who Switching from vitamin K antagonists to direct oral anticoagulants, published in the Journal of Thrombosis and Haemostasis
    • 08 Mar 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top